4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Mingfeng He, Chanjuan Gong, Yinan Chen, Rongting Chen, Yanning Qian. Effect of remimazolam vs. propofol on hemodynamics during general anesthesia induction in elderly patients: Single-center, randomized controlled trial[J]. The Journal of Biomedical Research, 2024, 38(1): 66-75. DOI: 10.7555/JBR.37.20230110
Citation: Mingfeng He, Chanjuan Gong, Yinan Chen, Rongting Chen, Yanning Qian. Effect of remimazolam vs. propofol on hemodynamics during general anesthesia induction in elderly patients: Single-center, randomized controlled trial[J]. The Journal of Biomedical Research, 2024, 38(1): 66-75. DOI: 10.7555/JBR.37.20230110

Effect of remimazolam vs. propofol on hemodynamics during general anesthesia induction in elderly patients: Single-center, randomized controlled trial

More Information
  • Corresponding author:

    Yanning Qian, Department of Anesthesiology and Perioperative Medicine, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. E-mail: yanning_qian@163.com

  • △These authors contributed equally to this work.

  • Received Date: April 27, 2023
  • Revised Date: July 13, 2023
  • Accepted Date: July 18, 2023
  • Available Online: August 28, 2023
  • Published Date: November 14, 2023
  • The current study aimed to compare the effects between remimazolam and propofol on hemodynamic stability during the induction of general anesthesia in elderly patients. We used propofol at a rate of 60 mg/(kg·h) in the propofol group (group P) or remimazolam at a rate of 6 mg/(kg·h) in the remimazolam group (group R) for the induction. A processed electroencephalogram was used to determine whether the induction was successful and when to stop the infusion of the study drug. We measured when patients entered the operating room (T0), when the induction was successful (T1), and when before (T2) and 5 min after successful endotracheal intubation (T3). We found that mean arterial pressure (MAP) was lower at T1–3, compared with T0 in both groups, but higher at T2 in the group R, while ΔMAPT0–T2 and ΔMAPmax were smaller in the group R (ΔMAPT0–T2: the difference between MAP at time point T0 and T2, ΔMAPmax: the difference between MAP at time point T0 and the lowest value from T0 to T3). Cardiac index and stroke volume index did not differ between groups, whereas systemic vascular resistance index was higher at T1–3 in the group R. These findings show that remimazolam, compared with propofol, better maintains hemodynamic stability during the induction, which may be attributed to its ability to better maintain systemic vascular resistance levels.

  • Dear Editor,

    Cardiovascular disease is the leading cause of deaths worldwide, with coronary artery disease (CAD) accounting for approximately 50% of its mortality. Dual antiplatelet therapy, including aspirin and a P2Y12 inhibitor, is the most important treatment for CAD patients undergoing percutaneous coronary intervention (PCI) to prevent recurrent ischemic events and cardiac death. Clopidogrel is one of the commonly used P2Y12 inhibitors. However, up to 30% of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity (HOPR), which is associated with the increased ischemic risks[1]. The causes of HOPR are multifactorial and complex. Polymorphisms of cytochrome P450 enzyme genes (such as CYP2C19) have been widely reported to influence platelet response to clopidogrel[2], which, however, may account for only 12% of HOPR[2]. The etiology for the rest of the patients exhibiting HOPR remains uncertain, which is a residual ischemic risk for CAD patients who are taking clopidogrel. The present study aims to investigate risk factors associated with HOPR in CAD patients undergoing PCI and receiving the dual antiplatelet therapy with aspirin and clopidogrel. The present study is a cross-sectional cohort study performed in the First Affiliated Hospital of Nanjing Medical University using our pre-registered database (Unique Identifier: NCT01968499), complied with the Helsinki declaration and local regulations, and was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University (No. 2011-SRFA-099). A written informed consent was obtained from each patient.

    CAD patients who had undergone PCI and taken clopidogrel (75 mg/day) combined with aspirin (100 mg/day) for more than five days were consecutively enrolled between April 2011 and October 2016 in the coronary care unit of the First Affiliated Hospital of Nanjing Medical University. We excluded patients who were: (1) intolerant to aspirin or clopidogrel; (2) with hematological diseases; (3) with baseline hemoglobin < 90 g/L, or platelet count < 80 × 109/L or > 450 × 109/L; (4) taking other antiplatelet agents or anticoagulants or any drugs that could potentially interfere with the antiplatelet efficacy of the study drugs; and (5) with end-stage diseases (e.g., cancer) or other conditions that were inappropriate to be recruited at the discretion of the investigators. The patients' demographics, present disease history, past disease history, personal history, physical examination, laboratory examination, and medications were recorded. In addition, venous blood was collected into two 2.7 mL vacutainer tubes containing 3.2% sodium citrate two hours after the patients took clopidogrel and aspirin. Platelet reactivities were measured by the light transmission aggregometry within two hours of the sampling. Platelet-rich plasma (PRP) was separated by centrifuging the blood sample at 200 g at 22 ℃ for 5 min, and platelet poor plasma (PPP) was obtained by spinning the remaining blood at 2465 g for another 10 min. Platelet counts were adjusted by adding PPP to PRP to achieve a count of 250 × 109/L. A total of 500 μL adjusted PRP was tested by a Chronolog aggregometer (Model 700, Chrono-log Corporation, Havertown, PA, USA) with 500 μL PPP as control. Platelet aggregation was induced by 2.5 μL adenosine diphosphate (ADP) with a final concentration of 5 μmol/L or 10 μL arachidonic acid (AA) with a final concentration of 1 mmol/L, and recorded as PLADP or PLAA, respectively. HOPR was defined as PLADP > 40%[3].

    SPSS version 25.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Continuous variables were presented as mean ± standard deviation, and categorical variables were expressed as frequencies or percentages. The independent Student's t-test or Chi-square test was used as appropriate to assess differences between the HOPR and non-HOPR groups, and the variables that were significantly different between the two groups were included in the logistic regression analysis to identify the factors associated with the HOPR. Covariates with P-values less than 0.05 in univariable regression analysis were selected for the inclusion in the multiple logistic regression model. A two-tailed P-value < 0.05 was considered statistically significant for all the tests.

    As a result, 1649 eligible patients were included in the analyses. By in platelet reactivity assessment, HOPR was observed in 389 (23.6%) patients. The baseline characteristics of patients are listed in Table 1.

    Table  1.  Baseline characteristics of patients with or without HOPR
    VariablesHOPR Non-HOPRP-value
    N[n (%)] or (mean±SD) N[n (%)] or (mean±SD)
    Female 389 117 (30.1) 1260 294 (23.3) 0.007
    Age (years) 389 64.4±10.3 1260 63.6±10.5 0.201
    BMI (kg/m2) 373 25.0±3.0 1182 24.6±3.1 0.023
    Smoking 387 160 (41.3) 1251 600 (48.0) 0.023
    Drinking 386 80 (20.7) 1248 314 (25.2) 0.075
    Hypertension 388 260 (67.0) 1258 831 (66.1) 0.728
    Diabetes mellitus 387 100 (25.8) 1253 331 (26.4) 0.822
    Hyperlipidemia 330 33 (10.0) 852 81 (9.5) 0.797
    PCI history 385 25 (6.5) 1249 127 (10.2) 0.030
    RBC (1012/L) 384 4.4±0.5 1237 4.5±0.6 0.010
    Hemoglobin (g/L) 384 134.1±15.3 1238 135.8±17.7 0.100
    WBC (109/L) 384 7.4±3.0 1238 6.9±2.4 0.004
    Neutrophil ratio (%) 384 64.0±11.8 1236 63.4±10.1 0.398
    Platelet (109/L) 384 189.2±56.4 1238 195.2±63.4 0.094
    ALT (U/L) 380 37.5±34.8 1242 36.3±50.3 0.660
    LDH (U/L) 374 310.0±338.9 1216 265.1±255.9 0.018
    γ-GGT (U/L) 344 44.2±65.0 1192 47.2±93.4 0.585
    TBIL (µmol/L) 346 13.3±6.1 1200 13.6±24.9 0.849
    DBIL (µmol/L) 345 4.2±2.1 1194 6.5±62.7 0.504
    IBIL (µmol/L) 345 9.1±4.4 1189 8.6±4.5 0.087
    BUN (mmol/L) 380 6.0±3.7 1238 8.0±41.1 0.347
    Creatinine (µmol/L) 380 77.9±22.0 1240 80.7±40.8 0.209
    Uric acid (µmol/L) 374 332.1±99.0 1221 346.1±93.8 0.013
    FBG (mmol/L) 370 6.3±2.2 1194 6.0±2.0 0.027
    HbA1c (%) 135 6.8±1.7 411 6.8±1.5 0.567
    TC (mmol/l) 373 4.3±1.2 1221 4.3±2.1 0.911
    TG (mmol/L) 374 1.6±0.9 1222 1.9±5.9 0.325
    LDL-C (mmol/L) 374 2.6±0.9 1220 3.4±12.1 0.231
    HDL-C (mmol/L) 374 1.1±0.3 1220 1.3±5.5 0.569
    Lp(a) (mg/L) 367 280.4±249.7 1210 282.7±267.2 0.883
    CK-MB (ng/mL) 312 39.1±79.1 968 36.4±138.7 0.750
    PCT (ng/mL) 135 0.4±1.3 370 1.0±2.8 < 0.001
    CRP (mg/L) 82 8.8±19.9 241 7.3±18.9 0.551
    PT (s) 332 11.9±1.2 1163 11.9±1.4 0.578
    APTT (s) 329 48.2±394.5 1160 26.7±9.9 0.323
    INR 332 1.4±3.1 1160 1.1±1.7 0.129
    PLADP (%) 389 50.4±7.7 1260 24.5±9.4 < 0.001
    PLAA (%) 389 5.2±9.8 1260 4.0±4.6 0.017
    PPIs 389 72 (18.5) 1260 233 (18.5) 0.994
    Statins 389 367 (94.3) 1260 1128 (89.5) 0.004
    CCBs 389 136 (35.0) 1260 413 (32.8) 0.424
    Diagnoses 377 1234 0.033
     SA 69 69 (18.3) 305 305 (24.7)
     UA 187 187 (49.6) 605 605 (49.0)
     NSTEMI 34 34 (9.0) 88 88 (7.2)
     STEMI 87 87 (23.1) 236 236 (19.1)
    Abbreviations: HOPR, high on-treatment platelet reactivity; BMI, body mass index; PCI, percutaneous coronary intervention; RBC, red blood cell; WBC, white blood cell; ALT, alanine transaminase; LDH, lactate dehydrogenase; γ-GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; BUN, blood urea nitrogen; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; TC, total cholesterol; TG, total triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; Lp(a), lipoprotein (a); CK-MB, creatine kinase-MB; PCT, procalcitonin; CRP, C-reactive protein; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio; PLADP, platelet aggregation induced by adenosine diphosphate; PLAA, platelet aggregation induced by arachidonic acid; PPIs, proton pump inhibitors; CCBs, calcium channel blockers; SA, stable angina; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; SD, standard deviation.
     | Show Table
    DownLoad: CSV

    Female, body mass index (BMI), smoking, PCI history, red blood cell (RBC) counts, white blood cell counts, lactate dehydrogenase, uric acid, fasting blood glucose, procalcitonin, PLAA, statin consumption, and CAD diagnosis were significantly associated with HOPR in the univariable logistic regression analyses (all P < 0.05) (Table 2). However, multivariable logistic regression analysis showed that only RBC count, BMI, and statin consumption were independently associated with HOPR (OR = 0.480, 95% CI: 0.302–0.763, P = 0.002; OR = 1.140, 95% CI: 1.054–1.232, P = 0.001; OR = 4.504, 95% CI: 1.004–20.208, P = 0.049, respectively) (Table 2).

    Table  2.  Logistic regression analysis for HOPR
    VariablesnUnivariate logistic regressionMultivariate logistic regression
    OR (95% CI)P-valueOR (95% CI)P-value
    Female vs. male 389 (117/272) 1.413 (1.097–1.820) 0.007
    BMIa 373 1.044 (1.006–1.084) 0.023 1.140 (1.054–1.232) 0.001
    Smoking vs. no smoking 387 (160/227) 0.765 (0.607–0.963) 0.023
    PCI history vs. no PCI history 385 (25/360) 0.614 (0.393–0.957) 0.031
    RBCa 384 0.757 (0.613–0.934) 0.010 0.480 (0.302–0.763) 0.002
    WBCa 384 1.070 (1.026–1.116) 0.002
    LDHa 374 1.001 (1.000–1.001) 0.007
    Uric acida 374 0.998 (0.997–1.000) 0.013
    FBGa 370 1.062 (1.009–1.119) 0.023
    PCTa 135 0.848 (0.736–0.977) 0.022
    Statins vs. no statins 389 (367/22) 1.952 (1.224–3.112) 0.005 4.504 (1.004–20.208) 0.049
    SA 69 1
    UA vs. SA 187/69 1.366 (1.004–1.860) 0.047
    NSTEMI vs. SA 34/69 1.708 (1.063–2.744) 0.027
    STEMI vs. SA 87/69 1.630 (1.138–2.333) 0.008
    aThe ORs for the continuous variables indicate that 1-unit increase of the variables is associated with a [(OR-1)×100] % increased risk of HOPR.Abbreviations: HOPR, high on-treatment platelet reactivity; OR, odds ratio; CI, confidence interval; BMI, body mass index; PCI, percutaneous coronary intervention; RBC, red blood cell; WBC, white blood cell; LDH, lactate dehydrogenase; FBG, fasting blood glucose; PCT, procalcitonin; SA, stable angina; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.
     | Show Table
    DownLoad: CSV

    This is the first study to show that in CAD patients undergoing PCI and treated with clopidogrel, the RBC counts were independently and negatively associated with HOPR. Karolczak et al[4] also reported a negative association between RBC counts and PLADP; however, their results were based on 251 volunteers without acute coronary syndrome, and the platelet activity was measured by multiplate impedance aggregometry. In contrast, the present study recruited a large number of CAD patients, adopted the gold standard light transmission aggregometry method, and was the first to reveal a negative association between RBC counts with HOPR.

    The effects of RBC on platelet aggregation may be mediated by ADP and nitric oxide (NO). ADP is stored in RBC and promotes platelet aggregation by binding to the P2Y12 receptor on the platelet surface, further activating glycoprotein (GP) Ⅱb/Ⅲa[4]. By contrast, NO, produced in the membrane and cytoplasm of RBC by the endothelial-type nitric oxide synthase (eNOS)[4], has been reported to inhibit the activation of GP Ⅱb/Ⅲa and platelet aggregation via the increase of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP)[5]. One study demonstrated that during platelet aggregation, the inhibitory effect of NO predominated over the activating effect of ADP[4]. In addition, studies have confirmed that RBC plays an important role in maintaining cardiovascular homeostasis and vascular function[6]. RBC is responsible for the synthesis and release of NO via the release of adenosine triphosphate (ATP) to activate the endothelial purinergic receptors[6]. ATP is degraded to ADP and adenosine by nucleotidases. Both ATP and ADP are present in approximately equal amount in platelet granules, while RBC releases 10 times more ATP than ADP[7]. Moreover, RBC is involved not only in the ATP release, but also in regulating adenosine uptake. Therefore, we hypothesize that patients with higher RBC counts produce more NO and ATP, which causes a stronger inhibition of platelet aggregation and a less likelihood of HOPR. However, future studies are needed to clarify the mechanism of this association between RBC counts and HOPR.

    Our results were also consistent with the reports indicating that BMI and statin consumption were independent risk factors for HOPR[89]. These may be explained by a decreased activity of CYP3A4 (a clopidogrel-related metabolic enzyme) and a relatively insufficient dose of clopidogrel in obese patients[9]. Most lipophilic statins, such as simvastatin and atorvastatin, are metabolized by the cytochrome P450 enzyme (mainly by CYP3A4) and competitively inhibit the metabolic activation of clopidogrel[8]. Thus, weight control is necessary for obese patients with CAD to reduce their risk of HOPR. Besides, lipid-lowering drugs that are less metabolized by CYP3A4 (e.g., rosuvastatin) may be more suitable for patients with HOPR. Several clinical variables, such as WBC counts and procalcitonin, were reported to be associated with platelet reactivity[10], but these associations were not confirmed in the present study. These may be explained by the biases from sample selection, sample size, differences in the detection methods, or different races of the study populations.

    The present study has some potential limitations. Although there were independent correlations of RBC counts, BMI and statins consumption with HOPR, the differences between groups (patients with or without high platelet reactivity) were subtle. The clinical value of the observations needs to be further explored in future clinical trials.

    In conclusion, the present study has revealed that low RBC counts, high BMI, and statin consumption may independently predict HOPR in CAD patients undergoing PCI and treated with clopidogrel.

    The present study was supported by the National Natural Science Foundation of China (Grant No. 82170351), the Jiangsu Province's Key Provincial Talents Program (Grant No. ZDRCA2016013), and the Special Fund for Key R&D Plans (Social Development) of Jiangsu Province (Grant No. BE2019754).

    Yours Sincerely,Qian Gu, Qin Wang, Rui Hua, Wenhao Zhang, Jianzhen Teng, Jiazheng Ma, Zhou Dong, Xiaoxuan Gong, Chunjian Li Department of Cardiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing, Jiangsu 210029,China.These authors contributed equally to this work.Chunjian Li and Xiaoxuan Gong. E-mails: lijay@njmu.edu.cn (Li) and xiaoxuangong@sina.com (Gong).

    None.

    CLC number: R614, Document code: A

    The authors reported no conflict of interests.

  • [1]
    Green RS, Butler MB. Postintubation hypotension in general anesthesia: a retrospective analysis[J]. J Intensive Care Med, 2016, 31(10): 667–675. doi: 10.1177/0885066615597198
    [2]
    Kozarek K, Sanders RD, Head D. Perioperative blood pressure in the elderly[J]. Curr Opin Anaesthesiol, 2020, 33(1): 122. doi: 10.1097/ACO.0000000000000820
    [3]
    Paton DM. Remimazolam: a short-acting benzodiazepine for procedural sedation[J]. Drugs Today, 2021, 57(5): 337–346. doi: 10.1358/dot.2021.57.5.3264119
    [4]
    Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation[J]. Curr Opin Anaesthesiol, 2020, 33(4): 506–511. doi: 10.1097/ACO.0000000000000877
    [5]
    Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase Ⅲ clinical trial[J]. Am J Transl Res, 2020, 12(8): 4594–4603. https://pubmed.ncbi.nlm.nih.gov/32913533/
    [6]
    Keam SJ. Remimazolam: first approval[J]. Drugs, 2020, 80(6): 625–633. doi: 10.1007/s40265-020-01299-8
    [7]
    Hu Q, Liu X, Wen C, et al. Remimazolam: an updated review of a new sedative and anaesthetic[J]. Drug Des Devel Ther, 2022, 16: 3957–3974. doi: 10.2147/DDDT.S384155
    [8]
    Liu T, Lai T, Chen J, et al. Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: a randomized, double-blind, controlled trial[J]. Pharmacol Res Perspect, 2021, 9(5): e00851. doi: 10.1002/prp2.851
    [9]
    Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class Ⅲ): results of a multicenter, randomized, double-blind, parallel-group comparative trial[J]. J Anesth, 2020, 34(4): 491–501. doi: 10.1007/s00540-020-02776-w
    [10]
    Qiu Y, Gu W, Zhao M, et al. The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: a randomized trial[J]. Front Med, 2022, 9: 938940. doi: 10.3389/fmed.2022.938940
    [11]
    Tang F, Yi J, Gong H, et al. Remimazolam benzenesulfonate anesthesia effectiveness in cardiac surgery patients under general anesthesia[J]. World J Clin Cases, 2021, 9(34): 10595–10603. doi: 10.12998/wjcc.v9.i34.10595
    [12]
    Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase Ⅱb/Ⅲ trial[J]. J Anesth, 2020, 34(4): 543–553. doi: 10.1007/s00540-020-02788-6
    [13]
    Chen L, Lu K, Luo T, et al. Observer's assessment of alertness/sedation-based titration reduces propofol consumption and incidence of hypotension during general anesthesia induction: a randomized controlled trial[J]. Sci Prog, 2021, 104(4): 368504211052354. doi: 10.1177/00368504211052354
    [14]
    Nakasuji M, Nakasuji K. Causes of arterial hypotension during anesthetic induction with propofol investigated with perfusion index and ClearSightTM in young and elderly patients[J]. Minerva Anestesiol, 2021, 87(6): 640–647. doi: 10.23736/S0375-9393.21.15226-5
    [15]
    Fernández-Candil JL, Terradas SP, Barriuso EV, et al. Predicting unconsciousness after propofol administration: qCON, BIS, and ALPHA band frequency power[J]. J Clin Monit Comput, 2021, 35(4): 723–729. doi: 10.1007/s10877-020-00528-5
    [16]
    Shin HW, Kim HJ, Jang YK, et al. Monitoring of anesthetic depth and EEG band power using phase lag entropy during propofol anesthesia[J]. BMC Anesthesiol, 2020, 20(1): 49. doi: 10.1186/s12871-020-00964-5
    [17]
    Dai G, Pei L, Duan F, et al. Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia[J]. Minerva Anestesiol, 2021, 87(10): 1073–1079. doi: 10.23736/S0375-9393.21.15517-8
    [18]
    Miyanishi M, Yaguramaki T, Maehara Y, et al. Three cases of difficulty in achieving definitive loss of consciousness with remimazolam[J]. JA Clin Rep, 2022, 8(1): 4. doi: 10.1186/s40981-021-00485-1
    [19]
    Shirozu K, Nobukuni K, Tsumura S, et al. Neurological sedative indicators during general anesthesia with remimazolam[J]. J Anesth, 2022, 36(2): 194–200. doi: 10.1007/s00540-021-03030-7
    [20]
    Feng SM, Liu J. Electrical velocimetry has limited accuracy and precision and moderate trending ability compared with transthoracic echocardiography for cardiac output measurement during cesarean delivery: a prospective observational study[J]. Medicine, 2020, 99(34): e21914. doi: 10.1097/MD.0000000000021914
    [21]
    Moura TS, Rosa SA, Germano N, et al. The accuracy of PiCCO® in measuring cardiac output in patients under therapeutic hypothermia: comparison with transthoracic echocardiography[J]. Med Intensiva, 2018, 42(2): 92–98. doi: 10.1016/j.medin.2017.03.007
    [22]
    Suehiro K, Tanaka K, Funao T, et al. Systemic vascular resistance has an impact on the reliability of the Vigileo-FloTrac system in measuring cardiac output and tracking cardiac output changes[J]. Br J Anaesth, 2013, 111(2): 170–177. doi: 10.1093/bja/aet022
    [23]
    Biais M, Mazocky E, Stecken L, et al. Impact of systemic vascular resistance on the accuracy of the pulsioflex device[J]. Anesth Analg, 2017, 124(2): 487–493. doi: 10.1213/ANE.0000000000001591
    [24]
    Fischer MO, Balaire X, Le Mauff De Kergal C, et al. The diagnostic accuracy of estimated continuous cardiac output compared with transthoracic echocardiography[J]. Can J Anaesth, 2014, 61(1): 19–26. doi: 10.1007/s12630-013-0055-z
    [25]
    Royse CF, Haji DL, Faris JG, et al. Evaluation of the interpretative skills of participants of a limited transthoracic echocardiography training course (H.A.R.T.scan® course)[J]. Anaesth Intensive Care, 2012, 40(3): 498–504. doi: 10.1177/0310057X1204000316
    [26]
    Seif D, Perera P, Mailhot T, et al. Bedside ultrasound in resuscitation and the rapid ultrasound in shock protocol[J]. Crit Care Res Pract, 2012, 2012: 503254. doi: 10.1155/2012/503254
    [27]
    Price ML, Millar B, Grounds M, et al. Changes in cardiac index and estimated systemic vascular resistance during induction of anaesthesia with thiopentone, methohexitone, propofol and etomidate[J]. Br J Anaesth, 1992, 69(2): 172–176. doi: 10.1093/bja/69.2.172
    [28]
    Saugel B, Bebert EJ, Briesenick L, et al. Mechanisms contributing to hypotension after anesthetic induction with sufentanil, propofol, and rocuronium: a prospective observational study[J]. J Clin Monit Comput, 2022, 36(2): 341–347. doi: 10.1007/s10877-021-00653-9
    [29]
    Couture P, Denault AY, Shi Y, et al. Effects of anesthetic induction in patients with diastolic dysfunction[J]. Can J Anaesth, 2009, 56(5): 357–365. doi: 10.1007/s12630-009-9068-z

Catalog

    Figures(6)  /  Tables(5)

    Article Metrics

    Article views (825) PDF downloads (449) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return